Vimarsana
Biggest News Aggregation in the World

Week Treatment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Week Treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Week Treatment Today - Breaking & Trending Today

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology -February 21, 2024 at 09:03 am EST - Vimarsana News

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology -February 21, 2024 at 09:03 am EST

Published: February 21, 2024

Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomCatalyst Or Company NasdaqCatalyst Pharmaceuticals IncLife Science AllianceExchange CommissionCatalyst PharmaceuticalsHealth CanadaStudy ReportsWeek TreatmentDuchenne Muscular DystrophySafety ProfileSanthera PharmaceuticalVamorolone OverBoys With Duchenne MuscularNorth Star Ambulatory AssessmentOrphan DrugRare Pediatric DiseasePromising Innovative MedicineProc Natl Acad Sci United StatesProduct CharacteristicsNorth AmericaDuchenne MuscularFast TrackFull Prescribing
Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia - Vimarsana News

Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia

Published: January 15, 2024

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the

Source: thailand-business-news.com
Related Topics:
Ping XiaoRodney SinclairNathan ChenAmber ChenHope Medicine IncCollege Of Future Technology Peking UniversityBayer AgInstitute Of Molecular MedicineHope MedicineOpen Label StudyEvaluate SafetyAndrogenetic Alopecia TreatedWeek TreatmentProfessor Rodney SinclairProfessor Rui Ping XiaoFuture TechnologyProfessor XiaoMolecular MedicinePeking UniversityThailand Business
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB - Vimarsana News

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

Published: November 13, 2023

/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb...

Source: prnewswire.com
Related Topics:
United KingdomHong KongUnited StatesJinzij WuAscletis Pharma IncHong Kong Stock ExchangePrnewswire Ascletis Pharma IncAmerican AssociationLiver DiseasesBreaking Abstract Poster PresentationChronic Hepatitisb Patients AfterWeek TreatmentSubcutaneously AdministeredInterim ResultsThyroid Hormone ReceptorShowed Little Drug InteractionSignificant Lipid ReductionComparable Pharmacokinetic ProfilesNon Alcoholic Fatty Liver DiseaseTwo PhaseChronic Hepatitisb Virus InfectionAscletis Pharma Inc
Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023 - Vimarsana News

Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023

Published: November 8, 2023

/PRNewswire/ -- Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for gout that dissolve uric acid crystals and prevent...

Source: prnewswire.com
Related Topics:
San DiegoUnited StatesAlex LoboLitain YehShunqi YanEuropean Alliance Of AssociationsTrial Using Dual Energy Computed TomographyArthrosi Therapeutics IncEnergy Computed TomographyAmerican College Of RheumatologyStern Investor Relations IncRobert KeenanChief Medical OfficerDual Energy Computed TomographyChief Executive Officer Litain YehChronic Gouty ArthritisSubcutaneous TophiProof Of Concept Trial Using Dual Energy ComputedAmerican CollegeEuropean AllianceSelective Uric Acid TransporterGout PatientsVarious Baseline Characteristics FollowingWeek TreatmentCrystal Arthropathies
Biogen Inc.: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS - Vimarsana News

Biogen Inc.: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS

Published: October 26, 2022

Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY (diroximel fumarate) consistent with previous

Source: finanznachrichten.de
Related Topics:
Nordrhein WestfalenUnited KingdomMaha RadhakrishnanCharles WeissmannWalter GilbertHeinz SchallerAllison ParksMike HenckeDiroximel FumarateKenneth MurrayUnilabs Customer Satisfaction SurveyChild DevelopmentObservational ProgramUniversity BochumExchange CommissionOutcomes On Child DevelopmentEuropean UnionResearch In Multiple SclerosisEuropean Committee For TreatmentEuropean CommitteeMultiple SclerosisChief Medical OfficerEfficacy ResultsHighlight Patient Reported OutcomesAnalysis Shows Impact